In Silico Prediction of Potential Compounds of Nigella sativa as Aromatase Agonists and Ability to Cross the Blood-Brain Barrier for treatment of Alzheimer’s Disease
Keywords:In silico, Nigella sativa, Aromatase agonists, Blood-Brain Barrier, Alzheimer’s Disease
Background: Alzheimer’s disease (AD), is a chronic neurodegenerative disease which condition is
characterized by a decline in memory, thinking skills, and the ability to perform basic activities of daily
living. Study showed that postmenopausal women with AD had a lower aromatase activity (p450 aromatase)
in the brain compared to menopausal women without AD. To improve cognitive function in AD patients,
Nigella sativa (NS) was found to have a protective effect on memory, and cognitive function. This study
therefore, aimed to investigate in silico prediction of potential compounds of Nigella sativa as aromatase
agonists and ability to cross the Blood-Brain Barrier (BBB) for treatment of Alzheimer’s Disease. Methods:
The data sets used in this study were collected from databases KnapSack Kanaya, PubChem, and PASS
server Way2Drug. HitPick and Autodock Vina was performed. Additionally, the systematic analysis
involved ADMET, LMMD, and SWISS ADME. Results and Discussions: In silico test results revealed the
most promising constituents in 36 active NS compounds that may have potential to reduce the severity of
the AD, owing to its anti-inflammatory, cytochrome p450 stimulants, free radical scavengers, antioxidants,
and immunomodulators. The ability of NS to cross the BBB was proven by admetSAR LMMD with an
analysis average value of 0.91 (from the highest value of 1). Further, NS can trigger cytochrome P450
aromatase activity via Quercetin 3-(6’’ ‘’-feruloylglucosyl)-(1->2)-galactosyl-(1->2)-glucoside which has a
better binding affinity value than its control (androstenedione). NS through oleic acid compounds may bind
to peroxisome proliferator-activated receptor gamma (PPRAG), similar to Rosiglitazone which may affect
transcription and activation regulation of PPARG. Conclusion: To be concluded, Nigella sativa could be
used as a potential medicinal plant for the treatment of Alzheimer’s disease.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details
This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions